Characteristics of study in the endpoint
| Variables | Group | P value | ||
| Total 1 122 171 (100) N (%) | Veterans 374 057 (33.3) N (%) | Non-veterans 748 114 (66.7) N (%) | ||
| Falls | <0.001 | |||
| Without | 1 031 680 (91.9) | 338 603 (90.5) | 693 077 (92.6) | |
| With | 90 491 (8.1) | 35 454 (9.5) | 55 037 (7.4) | |
| Gender | <0.001 | |||
| Female | 228 402 (20.4) | 73 298 (19.6) | 155 104 (20.7) | |
| Male | 893 769 (79.6) | 300 759 (80.4) | 593 010 (79.3) | |
| Age | 78.0±7.2 | 80.1±6.5 | 77.0±7.3 | <0.001 |
| Age group (years) | <0.001 | |||
| 65–74 | 408 190 (36.4) | 84 862 (22.7) | 323 328 (43.2) | |
| 75–84 | 514 627 (45.9) | 203 872 (54.5) | 310 755 (41.5) | |
| ≥85 | 199 354 (17.8) | 85 323 (22.8) | 114 031 (15.2) | |
| Season | 0.147 | |||
| Spring | 380 246 (33.9) | 126 741 (33.9) | 253 685 (33.9) | |
| Summer | 278 254 (24.8) | 92 434 (24.7) | 185 820 (24.8) | |
| Autumn | 197 359 (17.6) | 66 188 (17.7) | 131 171 (17.5) | |
| Winter | 266 132 (23.7) | 88 694 (23.7) | 177 438 (23.7) | |
| Urbanisation | <0.001 | |||
| High | 310 836 (27.7) | 82 269 (22.0) | 228 567 (30.6) | |
| Medium | 561 495 (50.0) | 230 791 (61.7) | 330 704 (44.2) | |
| Low | 249 840 (22.3) | 60 997 (16.3) | 188 843 (25.2) | |
| Level of care | <0.001 | |||
| Non-medical centre | 713 792 (63.6) | 220 496 (58.9) | 493 296 (65.9) | |
| Medical centre | 408 379 (36.4) | 153 561 (41.1) | 254 818 (34.1) | |
| Veterans hospital | <0.001 | |||
| Without | 949 503 (84.6) | 249 175 (66.6) | 700 328 (93.6) | |
| With | 172 668 (15.4) | 124 882 (33.4) | 47 786 (6.4) | |
| ISS ≥16 | <0.001 | |||
| Without | 1 116 550 (99.5) | 372 822 (99.7) | 743 728 (99.4) | |
| With | 5621 (0.5) | 1235 (0.3) | 4386 (0.6) | |
| Comorbidities | ||||
| Mental disorder | 146 081 (13.0) | 61 850 (16.5) | 84 231 (11.3) | <0.001 |
| Eye disease | 124 737 (11.1) | 58 711 (15.7) | 66 026 (8.8) | <0.001 |
| HTN | 618 430 (55.1) | 226 751 (60.6) | 391 679 (52.4) | <0.001 |
| Hyperlipidaemia | 98 427 (8.8) | 32 259 (8.6) | 66 168 (8.8) | <0.001 |
| Atherosclerosis | 27 848 (2.5) | 10 458 (2.8) | 17 390 (2.3) | <0.001 |
| COPD | 310 717 (27.7) | 114 072 (30.5) | 196 645 (26.3) | <0.001 |
| IHD | 319 667 (28.5) | 120 945 (32.3) | 198 722 (26.6) | <0.001 |
| HF | 178 935 (15.9) | 65 725 (17.6) | 113 210 (15.1) | <0.001 |
| CD | 307 914 (27.4) | 103 809 (27.8) | 204 105 (27.3) | <0.001 |
| RA | 49 639 (4.4) | 19 159 (5.1) | 30 480 (4.1) | <0.001 |
| PUD | 62 556 (5.6) | 24 517 (6.6) | 38 039 (5.1) | <0.001 |
| Liver disease | 107 109 (9.5) | 32 387 (8.7) | 34 722 (10.0) | <0.001 |
| DM | 336 143 (30.0) | 112 864 (30.2) | 223 279 (29.8) | <0.001 |
| Haemiplegia | 55 355 (4.9) | 17 852 (4.8) | 37 503 (5.0) | <0.001 |
| CKD | 207 519 (19.5) | 68 396 (18.3) | 139 123 (18.6) | <0.001 |
| Cancer | 300 719 (26.8) | 96 669 (25.8) | 204 050 (27.3) | <0.001 |
χ2/Fisher’s exact test on category variables and t-test on continue variables. The comorbidities are listed in the online supplementary table S1.
CD, cerebrovascular disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HF, heart failure; HTN, hypertension; IHD, ischemic heart disease; ISS, injury severity score; PUD, peptic ulcer disease; RA, rheumatism.